.png){kind=icon}
.png){kind=icon}
Return
Breaking immune isolation in glioblastoma
.png){kind=icon}
OA
AI
J
K
DOI：10.1016/j.drup.2026.101412.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Glioblastoma (GBM) represents one of the prototypical immune-cold tumors, characterized by profound immune suppression, T-cell exclusion, low neoantigen burden, and a highly immunosuppressive myeloid-dominant tumor microenvironment (TME). Despite advances in immunotherapy, including immune checkpoint blockade (ICB), CAR-T cells, and cancer vaccines, clinical benefits remain limited. This review synthesizes emerging evidence on multi-modal strategies aimed at reprogramming the cold TME into an immunologically active state. We highlight innate immune agonists, oncolytic virotherapy, precision nanomedicine, metabolic modulation, and radiotherapy-immune synergies. We further propose an integrated framework combining spatial immunomics, targeted delivery technology, and TME-specific engineering to overcome the therapeutic bottlenecks of GBM.
Keywords:
Immune-cold tumor microenvironment (Cold TME)
Multi-modal Immunotherapy
Innate
Immune activation (STING / TLR / RIG-I)
Myeloid reprogramming
Spatial
Immunomics
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
21.7
Papers:
1.0K
Citations:
7.1K
Organization
No organization information available